Nurix Therapeutics (NRIX) announced the initiation of the DAYBreak clinical trial, a pivotal single-arm Phase 2 study of bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia. DAYBreak and the planned Phase 3 confirmatory study of bexobrutideg will evaluate the 600 mg dose taken once daily. The selection of the 600 mg dose follows the completion of the analysis of data from a randomized cohort within the Phase 1b study comparing 200 mg and 600 mg in accordance with Project Optimus and reflects alignment with global regulators including the U.S. FDA, the U.K Medicines and Healthcare products Regulatory Agency, and the European Medicines Agency.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics initiated with an Outperform at Mizuho
- Promising Potential and Strategic Pipeline: A Buy Recommendation for Nurix Therapeutics
- Promising Clinical Results of NX-1607 Support Buy Rating for Nurix Therapeutics
- Nurix Therapeutics announces new clinical data from Phase 1a study NX-1607
- Nurix Therapeutics: Strong Cash Position and Upcoming Clinical Milestones Justify Buy Rating Despite Larger Net Loss